📊 ISPC Key Takeaways
Is iSpecimen Inc. (ISPC) a Good Investment?
iSpecimen exhibits severe fundamental deterioration with collapsing profitability, negative cash flows, and acute liquidity distress. The company operates at massive losses (-335% operating margin) while burning cash, with a current ratio of 0.63x indicating insufficient short-term liquidity to cover immediate obligations.
iSpecimen’s fundamentals are severely impaired, with shrinking revenue, deeply negative operating and net margins, and negative free cash flow that far exceeds its revenue base. Liquidity is weak, leverage is elevated relative to its small equity base, and the current cash position appears insufficient to comfortably support ongoing losses without additional financing or operational improvement.
Why Buy iSpecimen Inc. Stock? ISPC Key Strengths
- Maintains positive cash balance of $2.8M providing short-term runway
- Asset base of $9.0M provides liquidation floor
- Recently reported data ensures metrics reflect current state
- The company still retains a cash balance of $2.78M, providing some near-term operating flexibility.
- Long-term debt is present but not overwhelmingly large in absolute dollars relative to total assets.
- Diluted EPS improved year over year, indicating losses narrowed somewhat on a per-share basis.
ISPC Stock Risks: iSpecimen Inc. Investment Risks
- Critical liquidity crisis with current ratio of 0.63x and negative operating cash flow of -$3.3M quarterly
- Revenue declining 6.4% YoY while operating losses expand significantly
- Unsustainable burn rate: negative free cash flow of -$3.3M per quarter will deplete cash reserves within 9 months at current burn rates
- Debt/Equity ratio of 1.12x with $3.4M long-term debt and negative earnings create refinancing risk
- No insider purchasing activity in 90 days signals loss of management confidence
- Negative interest coverage of -349.4x indicates inability to service debt from operations
- Revenue declined 6.4% year over year, pointing to weak growth quality and limited operating traction.
- Profitability is extremely poor, with operating margin of -335.1% and net margin of -292.3%.
- Financial health is strained by a 0.63x current ratio, negative operating cash flow, and debt-to-equity of 1.12x.
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue stabilization and path to positive operating cash flow
- Gross margin sustainability and operating expense reduction initiatives
- Current ratio trend and working capital management
- Debt covenant compliance and refinancing needs
- Revenue growth and evidence of sustained customer demand recovery
- Operating cash burn relative to cash balance and working capital liquidity
iSpecimen Inc. (ISPC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ISPC Profit Margin, ROE & Profitability Analysis
ISPC vs Healthcare Sector: How iSpecimen Inc. Compares
How iSpecimen Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is iSpecimen Inc. Stock Overvalued? ISPC Valuation Analysis 2026
Based on fundamental analysis, iSpecimen Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
iSpecimen Inc. Balance Sheet: ISPC Debt, Cash & Liquidity
ISPC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: iSpecimen Inc.'s revenue has remained relatively flat over the 5-year period, with a 7% decline. The most recent EPS of $-17.58 indicates the company is currently unprofitable.
ISPC Revenue Growth, EPS Growth & YoY Performance
ISPC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $2.7M | -$1.4M | $-2.10 |
| Q2 2024 | $1.6M | -$2.1M | $-0.49 |
| Q1 2024 | $2.3M | -$2.4M | $-0.27 |
| Q3 2023 | $2.6M | -$2.1M | $-0.23 |
| Q2 2023 | $1.6M | -$2.4M | $-0.30 |
| Q1 2023 | $2.5M | -$2.4M | $-0.25 |
| Q3 2022 | $2.6M | -$1.4M | $-0.22 |
| Q2 2022 | $2.3M | -$1.4M | $-0.30 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
iSpecimen Inc. Dividends, Buybacks & Capital Allocation
ISPC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for iSpecimen Inc. (CIK: 0001558569)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ISPC
What is the AI rating for ISPC?
iSpecimen Inc. (ISPC) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 95% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ISPC's key strengths?
Claude: Maintains positive cash balance of $2.8M providing short-term runway. Asset base of $9.0M provides liquidation floor. ChatGPT: The company still retains a cash balance of $2.78M, providing some near-term operating flexibility.. Long-term debt is present but not overwhelmingly large in absolute dollars relative to total assets..
What are the risks of investing in ISPC?
Claude: Critical liquidity crisis with current ratio of 0.63x and negative operating cash flow of -$3.3M quarterly. Revenue declining 6.4% YoY while operating losses expand significantly. ChatGPT: Revenue declined 6.4% year over year, pointing to weak growth quality and limited operating traction.. Profitability is extremely poor, with operating margin of -335.1% and net margin of -292.3%..
What is ISPC's revenue and growth?
iSpecimen Inc. reported revenue of $1.9M.
Does ISPC pay dividends?
iSpecimen Inc. does not currently pay dividends.
Where can I find ISPC SEC filings?
Official SEC filings for iSpecimen Inc. (CIK: 0001558569) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ISPC's EPS?
iSpecimen Inc. has a diluted EPS of $-1.54.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ISPC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, iSpecimen Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ISPC stock overvalued or undervalued?
Valuation metrics for ISPC: ROE of -178.5% (sector avg: 15%), net margin of -292.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ISPC stock in 2026?
Our dual AI analysis gives iSpecimen Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ISPC's free cash flow?
iSpecimen Inc.'s operating cash flow is $-3.3M, with capital expenditures of $454.0. FCF margin is -177.1%.
How does ISPC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -292.3% (avg: 12%), ROE -178.5% (avg: 15%), current ratio 0.63 (avg: 2).